Today before the opening bell, Cardium Therapeutics announced that Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation’s leading independent proxy advisory firms, each recommend that Cardium’s stockholders vote “FOR” all proposals in the proxy statement and recommends a “1 Year” advisory say on pay frequency with respect to the matters that will be considered at the company’s annual meeting scheduled for June 6, 2013.

“We are pleased that Glass Lewis and ISS, the leading independent proxy and corporate governance advisory firms whose recommendations are relied upon by institutional shareholders, have recommended in favor of all proposals contained in our recent proxy statement. Each of these firms recommend a vote “For” the following: (1) re-election our Class I Directors, Edward W. Gabrielson, M.D. and Lon E. Otremba; (2) approval of the compensation paid to our named executive officers; (3) approval of the sale of the Series A Convertible Preferred Stock; (4) approval of a reverse stock split (5) approval of an increase to authorized common stock; and (6) ratification of the selection of our independent auditors. Our Board of Directors encourages all stockholders to submit their proxies in support of the Company’s proposals,” stated Christopher J. Reinhard, Cardium’s Chairman and CEO.

Cardium’s proxy statement and any other materials filed by the company with the SEC can be obtained at the SEC’s website at www.sec.gov or from www.cardiumthx.com. Only stockholders who held the company’s common stock as of the record date of April 26, 2013 are eligible to vote at the annual meeting. As always, the proxy statement should be read carefully before making any voting decision.

Those who have questions about the upcoming, voting methods, or proxy materials should contact Cardium’s proxy advisor, Georgeson, at 888-219-832.

For more information, visit www.cardiumthx.com

Let us hear your thoughts below: